Jade Biosciences, Inc. (JBIO) Stock Score, Valuation & Financial Research

Jade Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for JBIO

Jade Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 13.41. These figures are a research snapshot, not a buy or sell recommendation.

What Jade Biosciences, Inc. does

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Jade Biosciences is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity financing to fund the research, development, and clinical testing of novel biologic therapies for autoimmune diseases.

Products and services

  • The company is developing a pipeline of monoclonal antibody therapies, including JADE101 for immunoglobulin A nephropathy, JADE201 for rheumatoid arthritis, and the preclinical program JADE301.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to conduct clinical trials and preclinical research; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Paragon Therapeutics, Inc. — The company has an option agreement with Paragon Therapeutics to license intellectual property for the development and commercialization of monospecific antibodies. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting critical unmet needs in autoimmune diseases Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical trials and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

JBIO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 13.41
Market capitalization:
816.13M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -153.24M
Free cash flow:
USD -94.89M
Cash:
USD 107.25M
Total debt:
USD 628K
EPS:
USD -2.75

What stands out

  • Free cash flow is USD -94.89M, negative for the stored period.
  • The balance sheet shows USD 107.25M of cash versus USD 628K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 106.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for JBIO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can JBIO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is JBIO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for JBIO to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of JBIO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research JBIO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.